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ABSTRACT 
 The significant increase in antimicrobial resistance over the past few years is 
a serious global public health concern, particularly as the development of new 
antimicrobial agents had been slow for many years. Infections with resistant 
organisms are associated with poor clinical outcomes and higher cost burdens. 
Determining antimicrobial resistance patterns can help identify problem areas and 
modify treatment practices to improve clinical outcomes. Additionally, identifying 
adjunctive therapies can also help improve clinical outcomes among infected 
patients. The objectives, hypotheses, methods and results of this dissertation are 
threefold: 
 
 Manuscript 1: The objective was to analyze antimicrobial resistance trends in 
E. faecalis and E. faecium between 2003 and 2015 in five acute care facilities of the 
Veterans Affairs New England Healthcare System as antimicrobial resistance 
patterns among Enterococcus have changed over the past decade. Using a multi-
center ecologic study design, we evaluated antimicrobial resistance patterns for blood 
and urine cultures of enterococci. In E. faecium urine cultures, a decline in gentamicin 
resistance, as well as a small decease in vancomycin resistance were observed. 
Enterococcus resistance towards ampicillin, linezolid, and tetracycline was stable 
over the study period. Daptomycin resistance did not emerge over the study period. 
 
 Manuscript 2: The objective was to evaluate the impact of statin exposure on 
clinical outcomes, including inpatient mortality and length of inpatient stay, among 
bacteremic patients. The hypothesis was that statin use would be associated with 
positive clinical outcomes compared to non-statin use. We conducted a retrospective 
cohort study using the deidentified Optum ClinformaticsTM (OptumInsight, Eden 
  
Prairie, MN) with matched Premier Hospital data (October 2009-March 2013). Our 
retrospective cohort study observed lower mortality for incident users and prevalent 
users continuing statin use during admission. Though non-significant in incident 
users, the point estimate was similar to that observed in other studies. 
 
 Manuscript 3: The objective was to identify a statin therapy duration among 
pre-defined baseline statin users at which use of statins minimizes the risk of inpatient 
mortality among bacteremic patients. The hypothesis was that a certain minimum 
duration of statin use during the hospitalization would improve survival. A case-
control design was used to test this hypothesis using the Optum ClinformaticsTM with 
matched Premier Hospital data (October 2009-March 2013). Classification and 
regression tree analysis was conducted among cases and controls matched on 
disease risk scores. Among matched pairs of cases and controls with at least 90 days 
of pre-admission statin use, the continuation of statin use during admission for at 
least 2 days provided a better survival benefit among bacteremic patients.
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PREFACE 
 This dissertation is written in the manuscript format, and is comprised of three 
manuscripts, which evaluated (1) antimicrobial resistance patterns in Enterococcus 
pathogens, (2) the impact of statin exposure on clinical outcomes in bacteremic 
patients, and (3) optimal statin adjunctive therapy duration among 
bacteremic patients.  
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1.1 Abstract  
Enterococcus faecalis and E. faecium antibiotic resistance trends from 2003-2015 in 
clinical blood and urine cultures were evaluated among the New England Veteran 
Affairs hospitals using generalized linear mixed models. Over 10,000 unique isolates 
were included. In E. faecium urine cultures, a decrease in gentamicin resistance was 
noted (mean 2.9%/year). Vancomycin resistance slightly decreased in E. faecium 
urine cultures (mean 0.1%/year). Daptomycin resistance did not emerge, while 
ampicillin, linezolid, and tetracycline resistance remained stable over the study 
period.    
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1.2 Introduction 
 
 Antimicrobial resistance among Enterococcus has been increasing in the 
United States (U.S.) over the past several years.1,2 These bacteria have developed 
resistance to nearly every antibiotic used for treatment.2,3 Further, the occurrence of 
resistance in enterococci to comparatively new antibiotics, such as daptomycin4 and 
tigecycline,5 as well as developing resistance to adjunctive therapies, such as 
gentamicin, is a substantial public health concern.2 Infections with resistant organisms 
are associated with poor clinical outcomes,6 and increased health and cost burdens.7 
As antibiotic resistance changes, enterococcal infections are becoming more difficult 
to treat, potentially leading to the administration of inappropriate empiric therapies8,9 
that could increase mortality risk.10 Vancomycin resistance in enterococci (VRE) has 
increased extensively in the past few decades, and is considered a "serious threat" as 
each year, 20,000 (or 30%) Enterococcus healthcare-associated infections are 
vancomycin-resistant causing an estimated 1,300 deaths in the U.S.11 With the 
changing epidemiology of infections,12,13 frequent review of resistance, with respect to 
historical patterns, is crucial to identifying problems with resistance and response to 
such changes, such as modifications to treatment practices.14 This study aimed to 
describe antimicrobial resistance trends of E. faecalis and E. faecium in a large, 
regional healthcare system. 
 
1.3 Methods 
 A multi-center ecologic study design was used to evaluate annual antibiotic 
susceptibility from 2003 to 2015 among blood and urine isolates from five New 
England Veteran Affairs (VA) Medical Centers (Boston MA, Providence RI, Togus 
ME, White River Junction VT, and West Haven CT), based on Clinical and Laboratory 
Standards Institute (CLSI) guidance15,16. Changes in the percent resistance over the 
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study period were assessed with generalized linear mixed models (GLMM). GLMM 
accounts for the clustered nature of the study design by incorporating correlations 
among responses through the inclusions of random effects in the linear predictor 
and/or by modeling the correlations among the data directly.16 Generalized models 
are commonly used when response variables have error distribution models other 
than a normal distribution.16 The general form of the model is: y  The 
events/trial syntax (number resistant/number of isolates tested for a given antibiotic) 
served as the response variable and the 'year' functioned as the independent 
categorical variable. The binomial distribution and logit link were used for all GLMM 
models due to the event/trial syntax of a dependent variable. To account for the 
interdependence of samples within the five facilities (clusters), 'facility' was included 
as a random effect in the GLMM models. Significance was defined as an α (alpha) of 
0.05 and all models were run in SAS 9.4 (SAS Institute, Cary, NC, USA). 
 
1.4 Results   
 Over the thirteen-year study period, 10,257 unique enterococci isolates were 
extracted from blood and urine culture sites, of which 86.7% (n=8,894) were E. 
faecalis [blood=585 (6.6%), urine=8,309 (93.4%)] and 13.3% (n=1,363) were E. 
faecium [blood=246 (18.0%), urine=1,117 (82.0%)]. 
 
 E. faecalis resistance remained steady between 2003 and 2015, except for 
resistance to tetracycline. We observed a significant increase in the annualized 
modeled change in tetracycline resistance for E. faecalis urine cultures (0.4%/year, 
mean isolates tested per year [mean n]=370, % resistance in 2003 and 2015 
[resistance y03]=66.1%, [y15]=70.7%, p<0.01, Figure 1). Vancomycin resistance in E. 
faecalis remained low, and decreased non-significantly by an average 0.43%/year in 
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blood (mean n=45, resistance y03=5.1%, y15=0.0%, p=0.67) and 0.16%/year in urine 
cultures (mean n=639, resistance y03=5.1%, y15=3.2%, p=0.26). Resistance to 
ampicillin, a commonly used therapy for E. faecalis infections,17,18 remained low and 
stable in both blood (resistance all years, <3.1%) and urine (resistance all years, 
<1.4%). Linezolid resistance was also low and stable in E. faecalis urine cultures 
(mean n=112, resistance y03=1.9%, y15=2.3%, p=1.00).  
 
 In E. faecium urine isolates, a small annual decrease of 0.10%/year in 
vancomycin resistance was observed (mean n=86, resistance y03=68.7%, 
y15=67.3%, p=0.01, Figure 2). While the trend was statistically significant, the clinical 
relevance of a 1.20% decrease in resistance over the study period may be negligible. 
Conversely, vancomycin resistance in E. faecium blood isolates increased non-
significantly by 1.59%/year (mean n=19, resistance y03=63.3%, y15=82.4%, p=0.70). 
In E. faecium urine cultures, a statistically significant decrease in gentamicin 
resistance was observed (2.93%/year, mean n=13, resistance y03=35.1%, 
y15=0.0%, p<0.0001). Tetracycline resistance increased significantly in blood 
(5.56%/year, mean n=11, resistance y03=50.0%, y15=100.0%, p<0.01) and urine 
isolates (0.21%/year, mean n=54, resistance y03=73.1%, y15=75.6%, p=0.01).  
 
 Resistance towards ampicillin remained high, but stable in E. faecium blood 
(mean 1.40%/year decrease, mean n=19, resistance y03=98.8%, y15=80.0%, 
p=0.81) and urine (mean 0.68%/year decrease, mean n=80, resistance y03=95.1%, 
y15=86.9%, p=0.07) cultures. Linezolid resistance in E. faecium was observed, but 
remained low and non-significantly decreased by 0.53%/year in urine (mean n=55, 
resistance y03=7.9%, y15=1.5%, p=0.69). We did not observe any daptomycin-
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resistant isolates in either E. faecalis (0/552) or E. faecium (0/195) from 2007 when 
daptomycin susceptibility testing began.  
 
1.5 Discussion 
 In this ecologic study conducted in New England VA Medical Centers between 
2003 and 2015, antibiotic resistance in enterococci was mostly stable. Decreased 
vancomycin resistance in E. faecium blood isolates was reported in an Italian study, 
with resistance dropping from 24.1% in 2003 to 4.3% in 2009, and remaining between 
4-6% until 2013.19 A report from the SENTRY Antimicrobial Surveillance Program 
(2011–2014) among 21 Latin American medical centers (11 nations) observed a 
vancomycin resistance rate of 50.3% in E. faecium and 2.3% in E. faecalis.20  
Vancomycin resistance in E. faecium was high in our study, however, we observed a 
small, but significant decrease in urine isolates which could be a result of successful 
infection control strategies and antimicrobial stewardship activities.21 In E. faecalis, 
vancomycin resistance was low and decreased non-significantly in both culture sites. 
This findings are positive considering the spread of VRE over the past two decades.22  
 
 Other encouraging results besides decreasing vancomycin resistance in E. 
faecalis, were the stable resistance rates or small decreases in resistance rates to 
conventional therapies,17 such as ampicillin, in E. faecium. Daptomycin has been 
approved by the Food and Drug Administration (FDA) to treat VRE due to in-vitro 
bactericidal activity against VRE,23 however, the emergence of daptomycin resistance 
for E. faecium has been observed recently.4,24 Another positive finding in our study 
was the non-emergence of daptomycin resistance in enterococci blood and urine 
cultures. 
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 An increasing trend of E. faecium resistance to ampicillin, which is used for 
the treatment of VRE faecalis and susceptible E. faecium, was reported in 28 
hospitals in Thailand, growing from 52.0% in 2000 to 84.1% in 2005.26 Ampicillin 
resistance in E. faecium is high,27-29 especially in VRE faecium.30 Similar to the 
current literature, ampicillin resistance rates in E. faecium remained high (>75%) in 
our study, despite non-significant decreases in both urine and blood cultures. 
Compared to the high ampicillin resistance in E. faecium, VRE faecalis strains usually 
remain susceptible to ampicillin.30 We also observed low ampicillin resistance in E. 
faecalis, which remained stable over the study period.  
 
 Tetracycline resistance in E. faecium increased in urine and blood cultures. 
While tetracycline exhibits clinically significant anti-enterococcal activity, it is generally 
considered a second-line agent and is seldom used for enterococci treatment.18 As a 
result, susceptibility testing against this antibiotic declined, and therefore, the 
tetracycline resistance was only tested in few blood isolates after 2010 (n<3), 
resulting in larger differences in percent resistance year to year. Tetracycline 
resistance increases were not as large in years when more isolates were tested.  
 
 Linezolid resistance was observed in 4 of 5 facilities in our study, but the rates 
remained stable and low (<3%) over the study period. Linezolid is approved by FDA 
for the treatment of VRE faecium infections31 and it remains a crucial therapy for 
linezolid-susceptible isolates of both E. faecalis and E. faecium. Linezolid resistance 
is usually low in enterococci and was rarely reported in VRE until the past few years, 
however, recent VRE outbreaks have resulted in higher rates of linezolid 
resistance.32-35 A recent study36 reported a linezolid resistance rate of 30.2% among 
E. faecalis urine isolates, but was only 0.8% in our study. Linezolid resistance in 
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enterococci has been linked with increasing linezolid use,37 highlighting the role of 
antibiotic selective pressure and resulting changes in antibiotic resistance.   
 
 E. faecalis and E. faecium susceptibility to ampicillin, linezolid, tetracycline, 
and vancomycin, was relatively stable. Though some of these resistance trends were 
statistically significant, the small changes in resistance may not be clinically relevant. 
The spread of multi-resistant enterococci has been associated with the 
selective antibiotic pressure in tertiary care institutions38 and patients with recurrent 
health-care exposures, so future research should quantify the impact of changing 
antibiotic pressure on antimicrobial resistance and clinical outcomes. 
 
 Our study findings may be useful for informing antimicrobial stewardship 
programs, which play a key role in directing empiric therapy and raising awareness of 
new problems with resistance, which in turn improves antimicrobial resistance39 and 
healthcare costs40. However, there are limitations to this study. First, this is an 
ecologic study of facility-level resistance. Individual patients could have contributed 
multiple isolates over the study period.41 Second, antimicrobial resistance in certain 
strains of enterococci may be attributed to prior use of antibiotics42 which could not be 
studied due to the lack of patient-level data. Third, the generalizability of the study will 
be limited to the New England VA population that consists mostly of older, white 
males. Forth, aggregated microbiology trend data offer less detailed information than 
active surveillance, although, they are adequate at estimating the prevalence of 
resistance.43 Fifth, there may have been differences in enterococci resistance rates 
across the 5 facilities. Lastly, our results are limited by the number of cultures taken 
and the changes in the number of isolates tested against a specific antibiotic over the 
study period. Small changes in resistance patterns in a large number of isolates 
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(mostly urine), may not be clinically significant but were statistically significant. 
Conversely, larger changes in resistance in blood isolates were not statistically 
significant due to a small number of isolates, but the changes may be clinically 
important.  
 
 In conclusion, despite concerns surrounding VRE outbreaks multi-drug 
resistance that makes the Enterococcus difficult to treat,2 we found stable 
vancomycin resistance in Enterococcus among VA Medical Centers in New England. 
Similarly, Enterococcus resistance was stable for other common treatments. 
Additionally, daptomycin resistance did not emerge over the study period and 
gentamicin resistance decreased.  
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Appendix  
Fig 1: Trends in E. faecalis resistance (2003-2015) for blood and urine 
cultures 
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Fig 2: Trends in E. faecium resistance (2003-2015) for blood and urine 
cultures 
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2.1 Abstract 
Background: Several meta-analyses and observational studies have reported 
improved clinical outcomes in patients with inflammatory conditions among users of 
statins.  
Objectives: To evaluate the impact of statin exposure on clinical outcomes in 
bacteremic patients. 
Methods: A retrospective cohort study was conducted using Optum ClinformaticsTM 
with matched Premier Hospital data to assess inpatient mortality and length of stay 
(LOS) among statin-exposed vs. non-exposed bacteremic patients hospitalized 
between April 2010-March 2013. Patients who received at least two consecutive days 
of antibiotic therapy within the first three days of hospital admission were included. In 
the primary analysis, only incident statin users were included to avoid the "healthy 
user" bias. Non-users were defined as patients without any pharmacy records for 
statins. Cox proportional hazards regression models, adjusted by propensity scores, 
were developed to evaluate the effect of statins on clinical outcomes. Secondary 
analyses were conducted among existing statin users.  
Results: Our study included 112 incident statin users and 1,597 non-users. Inpatient 
mortality in bacteremic patients was non-significantly lower among statin users 
compared to non-users (adjusted hazard ratio [HR] 0.45, 95% confidence interval [CI] 
0.18-1.16). Reduction in inpatient mortality was significant among existing statin 
users with at least 90 days of continuous therapy prior to admission, who continued 
statin therapy during the admission (n=232, HR 0.37, 95% CI 0.14-0.96), and was 
non-significant among existing users not continuing statin therapy during the 
admission (n=401, HR 1.12, 95% CI 0.75-1.86). LOS was similar between all groups. 
Conclusion: Our retrospective cohort study observed lower mortality for incident 
users and existing users continuing statin use during admission. Though non-
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significant in incident users, the point estimate was similar to that observed in other 
studies. 
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2.2 Introduction 
 Bloodstream infections are the sixth most common principal reason for 
hospitalization, accounting for 836,000 hospital stays in 2009.1 Moreover, it is the 
most expensive cause of hospitalization in the United States (U.S.), accruing almost 
$15.4 billion in collective hospital costs in 2009.1 Statins, inhibitors of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase, decreases cardiovascular events among 
patients with elevated cholesterol.2 Protective effects with statins have been observed 
in inflammatory conditions, such as bacteremia3-6, sepsis7-9, pneumonia, and other 
infections in terms of 30-day, 90-day, in-hospital, and long-term (>1 year) mortality 
reductions, and these protective effects have been most pronounced in bacteremic 
patients.10  
 
 The specific mechanism by which mortality is reduced among patients with 
bacteremic infections remains undefined. A proposed mechanism has been the 
moderation of the overall inflammatory response.11 Other previously observed anti-
inflammatory effects with statins have included lowering of C-reactive protein (CRP), 
chemokine release (MCP-1, RANTES), cytokines (IL-1β, TNF α, IL-6, IL-8), and 
adhesion molecules (P-selectin, VLA 4, CD11a, CD11b, CD18).12,13 Statins may also 
have a direct antimicrobial effect14, and possible antibacterial activity of statins 
against a variety of pathogens may be attributed to their ability to suppress cell 
growth, and to promote apoptosis.15-17 In murine models, statin treatment inhibits 
apoptosis in sepsis18, reduces nitric oxide overproduction19, regresses the endotoxic 
shock induced damaged vascular responsiveness19, and also improves survival as it 
maintains cardiac function and hemodynamic status after an onset of sepsis.20 A 
randomized double-blind placebo-controlled trial among patients with acute bacterial 
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infections found a significant reduction in the levels of inflammatory cytokines among 
statin users.21  
 
 A number of meta-analyses10,22 and observational studies4-6,23 have reported 
survival benefits among bacteremic patients exposed to statins compared to those 
not exposed to statins. However, published research has not reached a consensus 
on this association as several studies failed to observe significant results24,25 and/or 
result estimates varied considerably.4,5,23,25 Optimal statin use duration required to 
provide mortality benefits is still unknown, but the continuation of statin use during 
hospital admission has been found to offer pronounced effects on survival.4  
 
 Differences between statin users and non-users in previous studies have 
varied by data source6,22, study designs10,22-25 and sample size of the statin user 
group.4,5,23 Observational studies evaluating this association have evident differences 
in statin user and non-user group, potentially causing confounding of the exposure-
outcome relationship.4,5,23 Many hospital based studies evaluating protective effects of 
statins did not have information about medical history or medication use prior to the 
admission.23,25,26 Therefore, this study aimed to determine whether the association 
between statins and better clinical outcomes was observed among a privately insured 
population with administrative data linked to hospital data. The primary objective of 
this study was to evaluate the impact of incident statin use, and secondarily existing 
statin exposures, on clinical outcomes, including inpatient mortality and length of 
hospital stay, in bacteremic patients exposed to statins versus those not exposed to 
statins in a large real-world clinical setting. 
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2.3 Methods 
2.3.1 Research Design and Methodology 
 A retrospective cohort study design was used to assess two different 
outcomes, inpatient mortality and length of hospital stay, among statin-exposed vs. 
non-exposed patients. A retrospective cohort study design was used because it 
allows the comparison  of individuals with differing exposures, which can be observed 
in order to determine the health effects of the exposure over a period of time.27 
 
2.3.2 Data Sources 
 This study was conducted using deindentified Optum  ClinformaticsTM 
(OptumInsight, Eden Prairie, MN) with matched Premier Hospital data (10/01/2009-
03/31/2013), which is an administrative claims database from a large commercial 
health plan (Optum ClinformaticsTM) matched with hospital data (Premier).  
 
2.3.3 Study Population 
 Included in the analysis were adult patients (>18 years) having a primary 
diagnosis for bacteremia or septicemia (International Classification of Diseases, 9th 
Revision, Clinical Modification [ICD-9-CM] codes 003.1, 020.2, 022.3, 036.2, 038.0, 
038.1, 038.10-038.12, 038.19, 038.2, 038.3, 038.40-038.44, 038.49, 038.8, 038.9, 
054.5, 449, 771.81, 995.91, 995.92, 790.7) caused by any organism during the study 
period.28 We only included patients with hospital admissions between 04/1/2010 and 
03/31/2013, to allow for a continuous enrollment period of 6 months prior to 
admission (Figure 1). Antibiotic therapy for each patient during the hospital stay was 
assessed. Patients who received at least two consecutive days of at least one 
antibiotic therapy for bacteremia29-32 within the first three days of the admission were 
included. For patients with multiple admissions for bacteremia, only the first 
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admission was included. Medication use was identified from both outpatient 
prescriptions and medications given during the hospital stay.  
 
2.3.4 Definition of Statin Use  
 For the primary analysis, we identified incident statin users, which was defined 
as those initiating a statin (i.e., atorvastatin, cerivastatin,  lovastatin, pravastatin, 
rosuvastatin and simvastatin) within 90 days of hospital admission, or during the 
hospitalization, after having not used statins in the three months prior to the initial 
pharmacy record. A one-day gap in therapy was allowed, including separate one-day 
gaps on several different occasions. Non-users were patients without any pharmacy 
records for statins from the study start period through hospital discharge. The date of 
the hospital admission was defined as the index date.   
 
 Secondary analyses were conducted among existing statins users. These 
analyses were conducted separately among patients who, irrespective of their statin 
initiation time, had at least a continuous 90-day exposure for statins prior to 
hospitalization and did not continue during admission (existing, outpatient-only users), 
and among patients who had a continuous statin exposure for at least 90 days prior 
to hospitalization and continued statins for at least the first 5 days after hospitalization 
(existing-continuous users). These existing statin users were compared with non-
users to assess differences in the outcomes.  
 
2.3.5 Outcomes 
 The primary outcome of interest in this analysis was inpatient mortality. The 
secondary endpoint that we evaluated was hospital length of stay. Inpatient mortality 
was defined as death occurring during the hospital stay. The length of hospital stay 
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was calculated as the number of days between hospital admission and the hospital 
discharge date. For the length of stay, patients who died during the admission were 
excluded from the analysis.  
 
2.3.6 Statistical Analysis 
 To identify baseline differences between the exposed and non-exposed 
groups, we analyzed demographic and clinical data including current and prior 
comorbidities.28 For categorical variables, if the assumptions for the chi-squared test 
were not met (expected count of 75% of cells >5), the Fisher's exact test was utilized. 
For continuous variables, the t-test was used for normally distributed data, and the 
non-parametric Wilcoxon Rank Sum test was used if the normality assumption of t-
test was violated as assessed graphically and the Shapiro-Wilk test for normality.  
 
The propensity score is the probability of treatment assignment conditional on 
observed baseline characteristics, derived from the inclusion of various demographic, 
hospitalization-related, and clinical characteristics in a logistic regression model. The 
propensity score attempts to mimic a randomized controlled trial (RCT) by balancing 
the exposure groups on observed baseline characteristics.33,34 In this study, the 
propensity score was the predicted probability of statin use, as calculated from the 
baseline covariates included in an unconditional logistic regression model which was 
built with manual backward elimination.34-37 The model included type of statin, other 
inpatient and outpatient medication use, such as calcium channel blockers, 
angiotensin-converting enzyme inhibitors, and diuretics. Further, we included type of 
antibiotic as differences in antibiotic therapy could have a large influence on 
bacteremic mortality. The propensity score model also controlled for various 
pathogens, where available, and comorbidities such as metabolic syndromes,  HIV, 
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cancer, and liver cirrhosis38. Initially, likelihood ratio tests were conducted on all 
independent variables individually and variables with a p-value <0.25 were 
considered as a candidate for inclusion in the multivariable model. Variables with a p-
value ≥0.05 were removed one at a time using backward elimination to determine the 
final propensity score model. We assessed multicollinearity among independent 
variables by review of correlation matrices and confirmed that all variance inflation 
factor (VIF) values were <3.39 Further, we t assessed goodness of fit with the 
Hosmer-Lemeshow goodness-of-fit test,39 and plotted propensity scores to review the 
overlap of propensity score between groups. Patients from the statin user and non-
user groups were stratified by propensity score quintile to achieve homogeneity 
between exposure groups within quintiles of the predicted probability of statin use.39 
Covariate balance within propensity score quintiles was reviewed.35,36 The general 
propensity score equation is illustrated below, where T is a binary treatment, Y is an 
outcome, and X are background variables: p ). The final 
propensity score model equations are included as footnotes in the results table.  
 
 Propensity score-adjusted Cox proportional hazards regression models were 
used to assess the impact of statin use on time to occurrence of inpatient mortality 
and the hazard ratios and 95% confidence intervals were calculated. We checked 
Cox proportional hazards models for non-informative censoring and proportionality 
using graphical displays, as well as the Supremum test.40 A PS-adjusted Cox 
proportional hazards model offers an estimate of the impact of treatment on survival 
after adjustment for variables which predict exposure. A hazard ratio greater than 1 
for inpatient mortality (dependent variable) means that the hazard is higher in the 
statin-exposed patients, and therefore the prognosis worse. On the other hand, a 
hazard ratio <1 implies a better prognosis for statin users. The general form of the 
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Cox proportional hazards model is: h(t|X) = h(t) exp(X1β1 + · · · + Xpβp). To evaluate 
the association of statin use and in-hospital mortality, without accounting for the rate 
at which deaths occur (time to event), we also computed the odds of inpatient 
mortality in statin users versus non-users using conditional logistic regression model, 
adjusting for PS quintiles. To assess the differences in length of stay between statin 
users and non-users, we developed a PS-adjusted Poisson regression model with log 
link. 
 
 The secondary analyses performed among existing statin users assumed the 
proximity of statin-exposure to the admission, regardless of previous duration, could 
offer protective effects. Separate propensity models were developed and used to 
adjust Cox-proportional hazards models. These models were used to study the 
survival benefits of existing, outpatient-only, as well as existing, continuous statin use. 
For all analyses, statistical significance was considered a p-value of ≤0.05. All 
statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). 
This study was reviewed and approved as exempt by the University of Rhode Island’s 
Institutional Review Board. 
 
2.4 Results 
 For the primary analysis, we identified 1,709 patients who met our inclusion 
and exclusion criteria (see Figure 2). This included 112 new initiators of statin use 
and 1,597 non-users. Among statin users, 53 (47%) initiated statin in the 90 days 
prior to admission and 59 (53%) anytime after admission. Of those initiating prior to 
admission, 33 (62%) continued statin therapy. The results of the descriptive analyses 
indicated that the cohorts differed with respect to baseline demographic and clinical 
characteristics. Among statin users vs. non-users (Table 1), significant (p<.01) 
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differences in age (median 61 vs. 53 years) and gender (39% vs. 53% females) were 
observed. The median Charlson comorbidity index (CCI) was significantly higher for 
statin users than non-users during the admission (2.7 vs. 2.1, p<0.0001; table 2) and 
also during the 6 months prior to admission (4.0 vs. 2.7, p<0. 0001). Admission from 
the emergency room occurred for 91% statin users and 96% non-users (p=0.01). 
Marital status, race, region, and admitting physician specialty were similar between 
statin users and non-users. Simvastatin (54.5%) and atorvastatin (28.6%) were the 
most commonly used statins. Inpatient mortality among statin users was non-
significantly lower (4.46% vs. 7.07%, p=0.4375) and LOS was higher (median 8.0, 
interquartile range [IQR] 3.5-10.0 vs. 7.3 days, IQR 3.0-9.0], p=0.052) compared to 
non-users. The crude absolute risk reduction (ARR) with statin use was 2.6%. 
Variables that differed significantly, no longer differed within PS quintiles. The final PS 
model c-statistic was 0.92, suggesting a strong model for predicting the probability of 
statin use.37  
 
 The PS-adjusted Cox proportional hazards regression model evaluating time 
to inpatient mortality demonstrated non-significantly lower inpatient mortality among 
bacteremic statin users (hazard ratio [HR] 0.45, 95% CI 0.18-1.16; Table 3). In the 
unadjusted analysis, the statin users had lower mortality rates than non-users (HR 
0.56, 95% CI 0.23-1.38), despite being older and having more comorbidities. After 
PS-adjustment, however, the inpatient mortality rates were slightly lower among statin 
users. Length of hospital stay in statin users and non-users (median 6.0, IQR 3.-10.0 
vs. 5.0 days, IQR 3.0-9.0, p=0.0821) was similar in adjusted analyses. In secondary 
analyses, we identified 401 existing statin users with only outpatient statin use. After 
PS-adjustment, we observed similar inpatient mortality among existing, outpatient 
only statin users (HR 1.12, 95% CI 0.75-1.86) vs. non-users. However, survival was 
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significantly higher in existing-continuous users (n=232, HR 0.37, 95% CI 0.14-0.96) 
compared to non-users. Statin users had non-significantly lower odds of inpatient 
mortality than non-users (odds ratio [OR] 0.44, 95% CI 0.14-1.44). 
 
2.5 Discussion 
 In the primary analysis of this retrospective cohort study among privately 
insured patients with bacteremia, the difference in inpatient mortality among incident 
statin users compared to non-users was not significant, although the point estimate 
(OR 0.44)  was similar to a meta-analysis published in 2010.22 This meta-analysis 
reported a 51% lower risk of mortality (OR 0.49, 95% CI 0.37-0.61) among patients 
with bacteremia, pneumonia, or sepsis, and 67% lower bacteremia-related mortality 
(evaluated in 4 studies out of 20, pooled OR 0.33, 95% CI 0.09-0.75) in statin users 
compared to non-statin users.22 In our study, statin users were significantly older and 
had a higher comorbidity burden compared to non-users, as observed in a previous 
study41 evaluating protective effects of statins in inflammatory conditions. 
 
 In our secondary analyses, we observed higher survival among existing-
continuous users. The magnitude of association for this analysis (63% lower 
mortality) was similar to a meta-analysis from 2012 that detected protective effects 
with statin use (62% lower mortality) against infection-related death in the 9 studies 
that focused on severe bacteremia (pooled OR 0.38, 95% CI 0.15–1.01), though 
these findings were also non-significant.10 This meta-analysis also observed a 29% 
decreased risk of all-cause mortality in patients with any type of infection (pooled OR 
0.71, 95% CI 0.64-0.78).10 These results suggest better clinical outcomes among 
statin users with infections. However, several of the studies included in the meta-
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analysis were subject to healthy user effects, by including existing statin users, and 
may not represent the true association between statin use and mortality.47-49,64 
 
 Our findings for existing, outpatient-only statin use are consistent with the 
results of two other meta-analyses that observed similar mortality rates among 
bacteremic patients with statin use vs. non-use. The first meta-analysis of 4 
randomized trials (1,818 patients) evaluating statin use in critically ill patients with 
severe sepsis did not observe a significant reduction compared to placebo in 28-day 
(risk ratio [RR] 0.95, 95% CI 0.72-1.27) and 60-day (RR 0.93, 95% CI 0.72-1.20) 
mortality rates.24 In the other meta-analysis of 7 randomized trials comprising 1,720 
patients,  there was no difference in 28-day mortality (statin vs. placebo RR 0.93, 
95% CI 0.46-1.89).42 The risk of mortality was similar between the statin and placebo 
groups in the aforementioned meta-analyses, which may be attributed to the inclusion 
of critically-ill patients with severe sepsis24, short statin therapy durations (14-28 
days),24,42 or stoppage of statin therapy during the crucial period of inflammation and 
hospital admission.42  
 
 The continuation of statin use during hospital admission was found to offer a 
greater benefit, in terms of inpatient mortality. Similar results have been observed in a 
retrospective cohort study.4 Additionally, a recent RCT reported a significantly lower 
28-day mortality rate (5% vs. 28%; P=0.01) in the subgroup of existing-continuous 
statin users.43 These results support continuing statins through the period of 
inflammation, as the inflammatory response has been found to be lower among 
patients on statins at the same time as they developed an infection.44,45  
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 Additional limitations of a number of the studies included in the 
aforementioned meta-analyses were (a) control for few confounders23,5,8,11,25, (b) lack 
of information about pre-hospitalization medication use23,25,26, (c) combined incident 
and existing statin use8,11,26,  and (d) combined pre-hospital and post-hospital use.26,46 
These limitations may explain the conflicting findings between studies in regards to 
the impact of statin use on mortality among patients with infections. 
 
Well-designed RCTs can overcome these limitations. Several RCTs have 
evaluated the anti-inflammatory or immunomodulatory effects of statins, including the 
ASEPSIS trial (EUCTR2005-004636-52), which investigated the difference in rates of 
sepsis converting to severe sepsis and of critical care admissions between statin-
treatment and placebo groups, and found the acute administration of atorvastatin in 
patients with sepsis may prevent sepsis progression.47 The “Statin Therapy in the 
Treatment of Sepsis” trial (NCT00676897), found significantly lower coenzyme Q10 
levels, which may be associated with the inflammatory cascade in septic shock, in 
septic shock patients compared to healthy controls.48 The “Statin for 
Immunomudulation in Sepsis” trial (NCT00452608) and “Effect of Atorvastatin on the 
Frequency of Ventilator-associated Pneumonia in Patients with Ischemic Stroke” trials 
(NCT01550419), evaluated if atorvastatin can improve inflammation in septic patients 
and if early use of statin (40mg oral atorvastatin during admission) prevents infections 
such as ventilator-associated pneumonia (VAP), respectively. The results of these 
trials are not yet available. 
 
 The effects of statin exposure on bacteremic mortality has been assessed 
more frequently than other clinical outcomes, including hospital and intensive care 
length of stay (LOS). According to the National Center for Healthcare Statistics 
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(NCHS), hospitalization rates for septicemia or sepsis more than doubled from 2000 
through 2008 and the average LOS was 75% longer than those hospitalized for other 
conditions.49 To our knowledge, only one study has explored the association of statin 
use with LOS, and found non-significant results for hospital (β = -0.8 days, 95% CI -
2.2-1.7 days) or intensive care unit LOS (β = -0.1 days, 95% CI -3.7 to 3.8 days) 
length of stay.25  
 
 The present study has several strengths. Firstly, we used administrative data 
from a major private insurer linked to hospital data which allowed us to evaluate 
medical history, previous medication use, as well as conditions present during the 
admission and all medication exposures during the hospitalization. Secondly, we 
attempted to account for "healthy user bias” by including incident statin users in our 
primary analysis since patients taking preventive medications, such as statins, are 
more likely to engage in healthy behaviors leading to favorable health outcomes 
compared to non-statin users.50,51 Additionally, patients taking preventive medications 
have a higher probability of being up-to-date with immunizations and having quit 
smoking, and are less likely to have been admitted to a nursing home or need 
advanced medical care.52 Third, we balanced baseline characteristics between statin 
users and non-users that were significantly different using PS methods in an effort to 
control for confounding. Lastly, to account for possible biases in socioeconomic and 
health behaviors,53 we included demographic and clinical characteristics in the PS 
models.  
 
2.6 Limitations 
 The results of this study have potential limitations. We could not study the 
protective effects of each statin separately due to small numbers. The effect of statins 
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on inpatient mortality in patients with sepsis may be different for individual statins.54 
We also could not assess dose-dependent effects, changes in statin therapy (drug or 
dose) prior to admission, at admission, or during the admission, or the effects of 
adherence due low sample sizes. In our review of statin doses, dispensing quantity in 
incident users mostly reflected moderate to high doses. As we used an administrative 
claims database for our analysis, we assumed outpatient statin exposure to be 
equivalent to filling a prescription. In the primary analysis, our definition of incident 
statin use was broad due to small numbers and included patients initiating prior to 
admission or after admission, and also included those not continuing statins during 
the admission (38%). As such, we could not evaluate the association using more 
specific definitions of incident statin use. 
 
Furthermore, there is a possibility of statins having a different impact on clinical 
outcomes based on the causative pathogen, since the mechanism of action is not 
exactly known and it may vary for different pathogens. Microbiology data was not 
available for potential causative pathogen, but we identified organisms using ICD-9 
codes, where available. Bacteremic treatment varies by organism type and we were 
only able to use general inclusion criteria of having received an antibiotic which may 
be used for bacteremia.29-32 Since we only evaluated a general bacteremic 
population, our results may not be generalized to pathogen-specific bacteremias. As 
such, patients without appropriate initial antibiotic treatment may have been included. 
Despite using propensity scores to control for confounding, we could not control for 
unmeasured confounding. We also could not differentiate bacteremic severity, 
although we included ventilation status and sepsis proxies using diagnosis-related 
groups (DRG).  
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2.7 Conclusions 
 In conclusion, our retrospective cohort study quantified the effect of both 
incident and existing statin use on clinical outcomes such as inpatient mortality and 
hospital length of stay among bacteremic patients in a real-world clinical population. 
Result estimates for incident and existing-continuous statin use, although non-
significant for incident users, were similar to previous meta-analyses that observed 
reductions in inpatient mortality after statin use among bacteremic patients. Further 
unaddressed questions related to this research question include appropriate statin 
exposure time and duration needed for maximum clinical benefits, and differences in 
the magnitude of each statin's protective effects. Future studies should control for 
healthy-user bias and differences in baseline characteristics between statin-users and 
non-users.  
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Appendix-  
Table 1. Demographic and hospitalization-related characteristics in incident 
statin users and non-users 
Characteristics 
Statin users 
(N=112) 
Non-users 
(N=1,597) P-value 
Age (years, median and 
IQR) 
61 53-69.5 53 41-62 
<.0001 
Gender 
0.0036 
Female 44 39.3 854 53.48 
Male 68 60.7 743 46.52 
Race 
0.8371 Black 10 8.9 167 10.5 
Other 18 16.0 270 16.9 
White 84 75.0 1160 72.6 
Census region 
0.4675 
East North Central 19 17.0 256 16.0 
East South Central 5 4.5 38 2.4 
Middle Atlantic 8 7.1 80 5.0 
Mountain 8 7.1 166 10.4 
New England <5 1.8 15 0.9 
Pacific 7 6.3 157 9.8 
South Atlantic 39 34.8 505 31.6 
West North Central 12 10.7 149 9.3 
West South Central 12 10.7 231 14.5 
Admission Type 
0.0116 
Emergency 102 91.1 1534 96.1 
Non-emergency 10 8.9 63 3.9 
Admitting Physician Facility 
0.5655 ICU/Surgery <5 3.6 68 4.3 
Medicine 42 37.5 671 42.0 
Other 66 58.9 858 53.7 
Diagnosis-related group (DRG) description 
0.0867 
Non-ventilation 101 90.2 1504 94.2 
Ventilation 11 9.8 93 5.8 
Hospital admission year 
0.1765 2010 37 33.0 385 24.1 
2011 38 33.9 572 35.8 
2012 37 33.0 640 40.1 
Data are median and interquartile range (IQR) or number and percent of patients. 
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Table 2. Clinical characteristics and health service utilization in incident statin 
users and non-users  
Characteristics 
Statin-users 
(n=112) 
Non-users 
(n=1,597) 
P-value 
Comorbidities (during admission) 
Charlson score (median and 
IQR) 
2 1-4 1 0-3 <.0001 
Elixhauser score (median and 
IQR) 
2 1-4 1 0-3 <.0001 
Amputation 14 12.5 114 7.1 0.0399 
Cardiac arrhythmia 38 33.9 344 21.5 0.0023 
Coronary heart disease 46 41.1 136 8.5 <.0001 
Chronic ulcer 17 15.2 95 6.0 0.0001 
Coma stupor and brain 6 5.4 33 2.1 0.0381* 
Chronic pulmonary disease 35 31.23 348 21.78 0.0201 
Chronic renal disease 26 23.2 209 13.1 0.0026 
Chronic respiratory disease 35 31.3 348 21.8 0.0201 
Depression 24 21.4 208 13.0 0.0120 
Diabetes complicated 16 14.3 61 3.8 <.0001* 
Diabetes uncomplicated 43 38.4 251 15.7 <.0001 
Dyslipidemia including 
hyperlipidemia 
57 50.9 167 10.5 <.0001 
Cellulitis or abscess 24 21.4 210 13.2 0.0136 
Coronary atherosclerosis & 
other heart diseases 
44 39.3 118 7.4 <.0001 
Congestive heart failure 27 24.1 149 9.3 <.0001 
Esophageal disorder 24 21.4 214 13.4 0.0175 
Chronic kidney disease 26 23.2 197 12.3 0.0009 
Other liver disease 8 7.1 276 17.3 0.0054 
Acute myocardial infarction 11 9.8 34 2.1 <.0001* 
Methicillin-resistant 
staphylococcus aureus 
11 9.8 69 4.3 0.0168* 
Myocarditis 11 9.8 86 5.4 0.0496 
Other circulatory disease 26 23.2 261 16.3 0.0327* 
Peripheral and visceral 
atherosclerosis 
13 11.6 55 3.4 0.0005* 
Hyperplasia of prostate 10 8.9 53 3.3 0.0065* 
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Skin or subcutaneous tissue 32 28.6 291 18.2 0.0119* 
Peripheral vascular disease 13 11.6 46 2.9 <.0001* 
Renal failure 61 54.5 615 38.5 0.0008 
Medication use (during admission) 
Anti-hypertensive medication 90 80.4 850 53.2 <.0001 
Diabetic medication 91 81.2 993 62.2 0.0075 
Comorbidities (6 months prior) 
Charlson score (median and 
IQR) 
3 1-6 1 0-3 <.0001 
Elixhauser score  (median and 
IQR) 
3 2-6 2 0-4 <.0001 
History of cardiac arrhythmia 36 32.1 299 18.7 0.0006 
History of coronary heart 45 40.2 122 7.6 <.0001 
History of chronic ulcer 17 15.2 96 6.0 0.0002 
History of chronic pulmonary 36 32.1 327 20.5 0.0035 
History of chronic renal 27 24.1 169 10.6 <.0001 
History of chronic respiratory 36 32.1 327 20.5 0.0035 
History of dyslipidemia 
including hyperlipidemia 
59 52.9 244 15.3 <.0001 
History of deficiency and other 
anemia 
39 34.8 392 24.6 0.0153 
History of coronary 
atherosclerosis diseases 
42 37.5 106 6.6 <.0001 
History of acute 
cerebrovascular disease 
15 13.4 46 2.9 <.0001* 
History of congestive heart 31 27.7 145 9.1 <.0001 
History of crushing or internal 
injury 
<5 2.7 9 0.6 0.0390* 
History of disorders diagnosed 
for non-adults 
5 4.5 11 0.7 0.0027* 
History of diabetes w/ 
complication 
35 31.3 167 10.5 <.0001 
History of diabetes w/o 
complication 
58 51.8 347 21.7 <.0001 
History of heart valve disorder 19 17.0 136 8.5 0.0026 
History of hepatitis . . 69 4.3 0.0208* 
History of hypertension w/ 
complication 
22 19.6 131 8.2 <.0001 
History of infective arthritis 7 6.3 32 2.0 0.0131* 
History of chronic kidney 22 19.6 147 9.2 0.0003 
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History of later effects of 
cerebrovascular disease 
7 6.3 39 2.4 0.0272* 
History of other diseases of 11 9.8 84 5.3 0.0415 
History of malaise and fatigue 34 30.4 315 19.7 0.0069 
History of acute myocardial 
infarction 
11 9.8 16 1.0 <.0001* 
History of myocarditis 16 14.3 70 4.4 <.0001* 
History of occlusion or stenosis 5 4.5 25 1.6 0.0421* 
History of other endocrine 13 11.6 84 5.3 0.0050 
History of other & ill-defined 
cerebrovascular diseases 
9 8.0 22 1.4 <.0001* 
History of other & ill-defined 
heart diseases 
14 12.5 89 5.6 0.0029 
History of peripheral and 
visceral atherosclerosis 
18 16.1 85 5.3 <.0001 
History of skin or 
subcutaneous tissue infections 
30 26.8 296 18.5 0.0314 
History of open wounds of 
extremities 
11 9.8 51 3.2 0.0017* 
History of mild liver disease 5 4.5 175 11.0 0.0258* 
History of peripheral vascular 
disease 
19 17.0 102 6.4 <.0001 
History of renal failure 31 27.7 262 16.4 0.0022 
History of valvular disease 18 16.1 124 7.8 0.0021 
Medication use history (6 months prior) 
Diabetic medication 38 34.0 554 34.7 0.1903 
Data are median and interquartile range (IQR) or number and percent of patients. 
*Values calculated using Fisher's Exact test 
 
 
 
 
 
 
 
Table 3. Clinical outcomes in statin users vs. non-users 
 43 
 
No. of events/No. of patients 
HR (95% CI) 
 
Incident statin 
users2 
Non-users Unadjusted 
Propensity 
Adjusted1) 
5/112 113/1,597 0.56 (0.23 - 1.38) 0.45 (0.18- 1.16) 
Existing outpatient 
statin users3 
Non-users  
 
44/401 113/1,597 1.57 (1.11-2.23) 1.12 (0.75-1.86) 
Existing outpatient 
statin users 
continuing statin 
use4 
Non-users  
 
6/232 113/1,597 0.34 (0.15-0.76) 0.37 (0.14-0.96) 
HR=hazard ratio; CI=confidence interval. 
1) Adjusted by propensity score quintiles (reference quintile I). 
2) The final PS model equation for predicting incident statin exposure.  
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3) The final PS model equation for predicting existing, outpatient-only statin exposure. 
 
4) The final PS model equation for predicting existing- continuous statin exposure. 
 
 
In the above equations, y is the probability of receiving a statin, α is the intercept, β’s 
are the coefficients on the independent variables and ε is standard error.   
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Figure 1. Study timeline for patient selection 
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Adult (≥18 years) inpatients with 
primary diagnosis of bacteremia 
(n=2,986) 
Exclusions: 
No antibiotic treatment within 
2 days of hospital admission 
(n=291) 
 
Premier data (n=25,649) Exclusions: 
Missing medical record or not 
eligible for 6 months before 
hospital admission (N=5,647) 
Non-adults and patients 
without primary bacteremic 
diagnosis (n=17,016) 
 
Patients receiving any antibiotic within 
2 days of hospital admission 
(n=2,695)  
Incident statin-
users 
n=112 
Initiated statin in 
the 90 days prior 
to the hospital 
admission or 
during the 
admission 
 
Non-users 
n=1,597 
No statin use  in 6 
months prior to 
the hospital 
admission or 
during the 
admission 
 
Figure 2:  Study cohort identification 
Existing, 
outpatient-only 
statin-users 
n=401 
At least 90 days 
of statin use prior 
to the hospital 
admission and did 
not continue 
during the 
admission 
 
Existing 
continuous statin-
users 
n=232 
At least 90 days 
of statin use prior 
to the hospital 
admission and 
continued at least 
first 5 days during 
the admission 
 
Exclusions: 
Other statin use not listed 
below (n=353) 
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Figure 3:  Adjusted proportional hazards among incident statin users vs. non-
users 
 
 
Note- On the x-axis, 'tmdc' represents "time to death". 
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3.1 Abstract 
Background: There is no consensus as to whether statin therapy should be 
continued among patients presenting to the hospital with bacteremia, and if so, what 
duration would be associated with better survival.  
 
Objectives: To identify a statin therapy duration that would decrease mortality in 
bacteremic statin users.  
Methods: Using Optum ClinformaticsTM with matched Premier hospital data 
(08/2009-03/2013), we conducted a case-control study among bacteremic statin 
users. Cases who died during the hospitalization were matched 1:1 to survivors on 
disease risk scores. Duration of statin therapy during the admission was evaluated in 
patients with at 3 months of pre-admission statin use. Classification and regression 
tree (CART) analysis was conducted to identify the optimal continued statin use 
duration which provided the lowest inpatient mortality, and logistic regression was 
used to calculate the odds of mortality associated with the duration identified in the 
CART analysis.  
Results:  We included 58 disease risk score matched pairs of cases and controls. 
Forty-one percent (n=47) of patients continued statin therapy during the hospital 
admission, of whom 15 (32%) were cases and 32 (68%) were controls. The CART 
analysis partitioned the continuation of statin therapy at 1.5 days, which predicted a 
lower inpatient mortality rate among bacteremic patients with statin exposure higher 
than this duration compared to those with lower duration, which included those not 
continuing statin therapy during the admission (29% vs. 62%). The odds of inpatient 
mortality for bacteremic patients with at least 2 days of continued statin use was 
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significantly lower than those with less than 2 days of continued use (OR 0.24, 95% 
CI 0.11-0.55).  
Conclusion: Among matched pairs of cases and controls with  statin use for at least 
90 days prior to the admission, the continuation of statins during the admission for at 
least 2 days demonstrated a survival benefit among bacteremic patients.
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3.2 Introduction 
 Bloodstream infections are the third most frequent hospital-wide infections in 
the Unites States (U.S.), along-with pneumonia (both 11%), following urinary tract 
infection (36%) and surgical site infection (20%).1 Between 2000 and 2009, inpatient 
mortality among patients with principal diagnoses of bloodstream infections remained 
high (16.7% and 16.3%, respectively).2 Evidence suggests that statins may improve 
survival in patients with bacteremia3-6 and sepsis,7-9 including 14-day6, 15-day3, 31-
180 day,10 and all-cause hospital mortality4,8, as well as persistent bacteremia (PB).6 
While numerous studies have found reduced mortality with statins in bacteremic 
patients, statin duration and measurement of outcomes differ across these studies.3-5 
As a result, rates of survival vary, particularly as statin exposure varies.4,10 Several 
studies not only observed a decline in inpatient mortality after continuing statin use 
during admission,4,10 but also an increase in mortality after cessation of statin 
therapy.4,11 Since the length of statin treatment time varies between studies, there is 
no consensus on the duration of statin continuation that would provide the maximum 
advantage in terms of clinical outcomes. 
 
  While several meta-analyses12,13 and observational4-6,10 studies observed 
protective effects with statins in bacteremia, one meta-analysis14 did not observe 
improvements in clinical outcomes after statin use. However, this meta-analysis was 
conducted among critically-ill patients with severe sepsis, and some of the included 
studies only had short durations of statin use.4,5,10 Other studies with shorter statin 
durations also did not demonstrate a statistically significant association between 
statin use and mortality.10,14,15 A recent RCT evaluating benefits of continued statin 
therapy on inflammatory parameters and sepsis among patients with pre-existing 
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statin use16 did not find clinical benefits of continuation. As such, there is a lack of 
evidence regarding the appropriate exposure duration needed for statins to provide 
the utmost protective effects in bacteremic patients. The main objective of this study 
was to identify a time breakpoint of statin continuation which minimized inpatient 
mortality among bacteremic patients. 
 
3.3 Methods 
3.3.1 Research Design and Methodology 
 A case-control study design was used to estimate a time breakpoint in statin 
continuation at which the highest clinical benefit would be seen in terms of survival 
(i.e., lowest inpatient mortality). A case-control study is an analytical study that 
compares individuals who have a specific outcome (cases) with a group of individuals 
that do not have the outcome (controls). A case-control design was utilized because it 
is the most effective study design for evaluating multiple exposures when an outcome 
is rare.17  
 
3.3.2 Data Sources 
 This study was conducted using deidentified Optum ClinformaticsTM 
(OptumInsight, Eden Prairie, MN) with matched Premier hospital data (10/01/2009-
03/31/2013) among adult (≥18 years) patients with a primary diagnosis of bacteremia 
during a hospital admission. This dataset is an administrative claims database from a 
large commercial health plan (Optum Clinformatics) matched with hospital data 
(Premier).  
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3.3.3 Study Population 
 Adult patients with continuous enrollment for at least six months in the 
commercial health plan prior to hospital admission were included. Patients were 
included if they were hospitalized between 04/01/2010 and 03/31/2013 with a primary 
diagnosis of bacteremia or septicemia (International Classification of Diseases, 9th 
Revision, Clinical Modification [ICD-9-CM] codes 003.1, 020.2, 022.3, 036.2, 038.0, 
038.1, 038.10-038.12, 038.19, 038.2, 038.3, 038.40-038.44, 038.49, 038.8, 038.9, 
054.5, 449, 771.81, 995.91, 995.92, 790.7)18 by any causative organism. We 
excluded patients who, on the first three days after hospital admission, did not receive 
a minimum of two successive days of at least one bacteremic antibiotic therapy.19-22 
The index date was defined as the date of the first hospital admission during the 
study period, and subsequent multiple hospital admissions were not considered for 
the analysis. From this cohort, only patients with a minimum of 3 months of 
continuous statin use in the 3 months prior to admission were selected for inclusion 
(Figure 1). 
 
3.3.4 Cases and controls 
  Cases included those who died during the admission. In a case-control study, 
controls should be drawn from the same population from which cases are derived, in 
order to reduce the chance that group differences account for the difference in the 
exposure being evaluated.23 Thus, controls were selected from the same cohort of 
adult patients who had a primary diagnosis of bacteremia on hospital admission and 
received an antibiotic therapy, but experienced a different outcome (i.e., no inpatient 
mortality). Controls were matched to cases on disease risk score (DRS).24 DRS is a 
confounder summary method, commonly used in case-control studies to control for 
confounding by calculating the predicated probability of an outcome in the absence of 
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exposure.25,26 A recent simulation study27 suggested the DRS model could cause 
higher bias due to misspecification at higher outcome incidences, however, when the 
outcome is rare, DRS matching would increase the statistical efficiency of case-
control studies. The DRS is considered a useful method in case-control studies,25 
especially when the association between covariates and exposure is modest 
(squared multiple correlation coefficient amid exposure and confounders <90%).28 
The stratified DRS is a retrospective balancing score and therefore it works in a 
similar manner in case-control studies as the propensity score works in cohort 
studies.26  
 
3.3.5 Statin duration 
 Among the patients with at least 90 days of statin therapy in the 90 days 
before admission, the primary exposure of interest was the period of continued statin 
use during admission. The statins included were atorvastatin, cerivastatin, fluvastatin, 
lovastatin, pravastatin, rosuvastatin and simvastatin. Statin use duration was counted 
as the number of days of statin use between initiation and the last pharmacy record 
without more than one day gap in therapy. The period of continued statin use during 
admission was considered to be an exposure among the patients having a similar, 
minimum pre-admission statin use of at least 3 months. A one day gap in therapy was 
allowed, but the gap was not counted in the calculation of the statin use period.   
 
3.3.6 Statistical Analysis 
 Disease risk scores (DRS) were calculated to control for confounding. A DRS 
is the probability of a patient having a particular outcome in the absence of the 
exposure.24,25 Therefore, we calculated DRS as the probability of inpatient mortality 
among unexposed patients, that is, statin users not continuing use post-admission. 
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Using likelihood ratio tests, we compared each independent variable to the null 
model. Variables with a p-value <0.25 in likelihood ratio tests were included in an 
initial multivariate model and removed using a backward elimination approach, if the 
p-value of the parameter estimate was less than 0.05 to arrive at the final DRS model. 
The model was checked for multicollinearity using variance inflation factor (VIF) and 
correlation matrices, and goodness of fit was checked using the Hosmer-Lemeshow 
goodness-of-fit test.29,30 The final DRS model c-statistics was 0.91. The full DRS 
model equation can be found in the footnote of the main results. Using nearest 
neighbor matching within a caliper of 0.25 distance, a single control was selected for 
each case.31 We checked DRS balance between cases and controls using graphical 
displays (see figure 2). 
 
 To partition statin continuation days associated with the lowest risk of death 
(i.e., highest survival), we conducted a classification and regression tree analysis 
(CART).32,33 The CART analysis, which includes an optimal tree selection based on 
pruning and cross-validation, identified subsets of patients at lowest risk of death and 
determined the influence of statin exposure in these subsets of patients. The CART 
method employs a recursive partitioning for building hierarchical binary classification 
trees. The CART model fits a simple prediction model within each partition. Each 
partition is binary, occurring on one explanatory variable at a time and at the point of 
maximum heterogeneity of the two groups with regards to the dependent variable. 
CART models are useful because of their non-parametric, non-linear structure.33 As a 
result, they do not make any distribution assumptions, they treat the data generation 
process as unknown, and they do not require a functional form for the predictors. 
Indeed, tree methods are probably one of the most easily interpreted statistical 
techniques; they are conceptually simple yet analytically powerful.33,34 In the CART 
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analysis, the primary dependent variable was inpatient mortality (case/control) and 
the independent variable was days of continued statin exposure during 
admission. The trees were automatically developed to forecast inpatient mortality by 
considering every possible cut-point on statin continuation duration at every node in 
the classification tree. We checked the fitness of the tree by plotting cross-validated 
error rate vs. size of a tree, and identified an appropriate complexity parameter 
(CP).33,34 Based on the split provided by the CART analysis, conditional logistic 
regression was conducted to  calculate the odds of mortality. All statistical analyses 
were conducted using either SAS version 9.4 (SAS Institute, Cary, NC) or R software 
version 3.2.0 (The R Foundation for Statistical Computing) with a recursive 
partitioning technique “rpart” package that was developed for Splus (Insightful 
Corporation, Seattle, WA) by Therneau and Atkinson.35 This study was reviewed and 
approved as exempt by the University of Rhode Island’s Institutional Review Board. 
 
3.4 Results 
 During the three-year study period, 61 (6.9%) patients died and 821 (93.1%) 
did not die during their hospital stay amongst the 882 patients with at least 3 months 
of statin use in the 3 months before admission. Using DRS matching, 58 controls 
were matched to 58 cases using nearest neighbor matching at a caliper distance of 
0.25. Due to matching, baseline characteristics were very similar between cases and 
controls in terms of age (median 68 vs. 67 years, p=0.8520; Table 1), gender (39.7% 
vs. 43.1% females, p=0.7992), race (20.7% vs. 15.5% non-whites, p=0.7637), as well 
as the Charlson comorbidity score during the admission (median=4 vs. 4, p=0.8239) 
and in the six months prior to admission (median=4 vs. 4, p=0.4959; Table 2). The 
length of hospital stay was significantly longer among controls compared to cases 
(median=9 vs. 5 days, p=0.0005). Of the 47 (41%) patients who continued statin use 
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during the hospital admission, 32% (n=15) were cases and 68% (n=32) were 
controls. The average statin therapy duration continued during admission among 
cases and controls was 1.5±3.7 vs. 4.5±7.5 days, respectively.  
 The CART analysis partitioned the dependent variable of statin therapy 
duration, suggesting differences in inpatient mortality at different statin continuation 
durations. See Fig. 3. The study included an equal number (n=58) of cases and 
controls, producing a 50% survival rate at the root node. The split at 1.5 days 
predicted patients with <2 days of continued-during-admission statin use (n=74, 64%) 
have 62.2% probability of inpatient mortality (n=46 of 74), while the patients with ≥2 
days of continued-during-admission statin use (n=42, 36%), have only 28.6% (n=12 
of 42) chances of inpatient mortality. In other words, among bacteremic patients with 
existing statin use, inpatient survival was higher among those continuing statins for at 
least 2 days after the admission compared to those not continuing or with 1 day of 
use (71.4% vs. 37.8%) and the odds of inpatient mortality was 76% lower (OR 0.24, 
95% CI 0.11-0.55). 
3.5 Discussion 
 In this DRS matched case-control study, we identified a specific continued 
statin use duration threshold required to provide the maximum survival benefit among 
bacteremic patients, which was the continuation of statin therapy for at least 2 days. 
The 76% lower odds of inpatient mortality among statin users continuing use for at 
least 2 days agreed with existing literature evaluating this association.4,5,10 A 
retrospective cohort study among bacteremic patients found a reduced adjusted 
hospital mortality rate (OR 0.39, 95% CI 0.17-0.91, p=0.029) in those taking statins 
prior to admission, which decreased even further with the continuation of statin during 
the admission (OR 0.06, 95% CI 0.01-0.44, p=0.0056).4 This study also observed 
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similar finding in terms of deaths attributable to bacteremia in patients with statin use 
only before admission (OR 0.29, 95% CI 0.10-0.86, p=0.025) versus continued during 
admission (OR 0.09, 95% CI 0.01-0.64, p=0.016).  
 
 Another study5 conducted among bacteremic patients taking a statin at the 
time of admission and continuing throughout the hospitalization at a Veterans Affairs 
Medical Center in Washington, identified a therapeutic benefit with statin continuation 
(adjusted OR 0.13, 95% CI 0.02–0.99). The aforementioned study included mostly 
males (99.5%), while females made up 41% of our study population.  
 
 Our findings imply that the statin use is necessary during a crucial phase of 
inflammation development, similar to previous studies36,37 observing a decline in 
inflammatory response among patients developing infections while on statin therapy. 
The extent of improvement in clinical outcomes after statin use among patients with 
inflammatory disorders is still a dilemma, and the mechanisms of action due to which 
statins provide clinical benefits remain unconfirmed. There are several possible 
reasons why existing statin use at the time of inflammation, is necessary to observe 
clinical benefits in bacteremic patients. Anti-inflammatory properties of statins have 
been credited to their ability to reduce C-reactive protein (CRP) and cytokines (IL-6, 
IL-8),38,39 and studies have demonstrated that the time required by statins to reduce 
CRP varies, based on statin dose, patient disease,40 and type of statin41,42. For 
example, pravastatin reduces CRP levels at 12 and 24 weeks,41 while simvastatin 
could reduce CRP within 14 days.42 Further, low levels (<20 mg/dL) of high-density 
lipoprotein (HDL) cholesterol) on the first day of severe sepsis was found to be 
associated with an increase in mortality and adverse clinical outcomes.43  
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 Our results differed from the results of a meta-analysis12 that evaluated an 
association between outpatient statin use and infectious disease-related mortality, 
with pooled ORs of 0.62 (95% CI 0.534-0.72), 0.68 (95% CI 0.53-0.89), and 0.86 
(95% CI 0.70-1.07) for 30-day, 90-day, and long-term (>1 year) mortality, 
respectively. Our results may differ from this meta-analysis12 as we only included 
bacteremia, while the meta-analysis included bacteremia, sepsis, pneumonia, and 
other infections in outpatient settings. Additionally, the meta-analysis only evaluated 
outpatient statin use prior to admission and continuation of statin use during 
admission was unknown. Conversely, we investigated both statin use before 
admission and continued during admission.  
 
 A recent propensity-score matched cohort study15 found non-significant 
beneficial effects with statin use. However, the authors note that pre-admission 
indications and statin therapy duration were not available. A recent RCT also did not 
observe benefits of continued statin therapy on inflammatory parameters and sepsis 
among existing statin users.16 However, this study has several methodological issues 
as pointed out in a correspondence by Bostock et. al.,44 including a vague primary 
endpoint, lack of information regarding previous statin therapy duration, and use of 
the Mann-Whitney test to evaluate the matched groups. 
 
 Our study is a step forward in the direction of identifying an optimal statin 
duration for inflammatory conditions. To the best of our knowledge, this is the first 
study in a large, privately insured population in the U.S. evaluating an optimal 
continued statin therapy duration among patients with inflammatory conditions. We 
utilized a machine-learning analysis method, CART, that allowed us to identify an 
exact statin therapy duration at which inpatient mortality was lowest among patients 
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with bacteremia. Other factors may affect the impact of statin therapy on mortality, 
including baseline differences in patient characteristics, differences in bacteremic 
severity, regional differences in infections, statin prescription patterns, pre-admission 
and post-admission comorbid conditions as well as medication use. However, we 
used DRS to match controls to cases in order to account for confounding. The 
strength of an observational study generally depends on the quality of the data 
source. However, we utilized administrative data from a large, national insurer, which 
is not affected by recall or surveillance bias. Further, used administrative and hospital 
linked data from a real-world clinical population with health-coverage from a major 
private payer.  
 
 Our study offers evidence regarding continuation of statin therapy in existing 
statin users presenting to the hospital with bacteremia. Although our findings indicate 
benefits with continuation of statins during admission, greater information is needed 
regarding the risks of continuation, in terms of adverse events, to enable a clear 
benefit-risk assessment. There is an ongoing controversy about the benefit-risk 
assessment of statins in general ("statin wars")45 between editors of two English 
medical journals, the British Medical Journal (BMJ) and Lancet. In 2014, the BMJ 
published two papers claiming the side effects from statins are much higher than 
reported in clinical trials, while statin trial leaders published a review identifying the 
benefits of statins in the Lancet in 2016. Statins are life saving medications for many 
patients with evaluated cholesterol and cardiovascular risks, however, for the 
potential for adverse effects also exist, as with all medications. Despite the well-
established benefits of statins in patients with cardiovascular diseases, statin side 
effects, such as liver damage, diabetes mellitus, and muscle pain, may outweigh the 
widely accepted benefits. Consequently, any future RCT evaluation of the association 
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between statin use and clinical outcomes in bacteremic patients should include a 
benefit-risk assessment.  
 
3.6 Limitations 
 Our study has a few limitations. First, we were unable to assess adherence or 
dose-dependent effects of statins that might affect bacteremic mortality. Depending 
on the severity of the infection, different statin doses and different statins may be 
used. While statin therapy may been continued more frequently in lower-risk patients, 
as clinicians hear about the potential protective effects of statins, there may 
channeling bias in the opposite direction, where more severe patients are kept on 
their statin therapy.46 Second, our study relied on a claims database, which raises the 
concern of misclassification due to coding errors throughout medical claims 
processing. Further, use of this database assumed actual exposure from prescription 
claims and hospital charges for medications. Third, we could not study differences in 
mortality with statin continuation duration in bacteremia caused by specific 
pathogens. A previous study26 observed greater protection with statins in S. aureus 
bacteremia compared to bacteremia caused by Gram-negative bacilli, while also 
suggesting greater survival in nosocomial versus community-associated 
bacteremia.26 Our study could not evaluate these differences. Moreover, the sample 
size of our study was small. Lastly, the limitations of CART analysis include an 
inability to fully describe the observed data due to uncertainty that remains in the 
prediction of the model and potential existence of multiple threshold values despite a 
single “optimal” split.47  
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3.7 Conclusions 
 In conclusion, this disease risk score matched case-control study conducted in 
a real-world clinical population identified a time breakpoint of statin continuation which 
maximized survival among bacteremic patients. Our results corroborate findings from 
previous studies which indicate continuation of statins during the hospital admission 
reduces mortality. The findings of our study are unique and add to the literature on 
regarding the minimal duration of continued statin use. 
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Appendix- 
Table 1. Demographic and hospitalization-related characteristics in cases and 
controls 
 
Data are median and interquartile range (IQR) or number and percent of patients. 
 
Characteristics Cases (n=58) Controls (n=58) P-value 
Age (years) 68 61-77 67 60-82 0.8520 
Gender 
0.7061 Female 23 39.7 25 43.1 
Male 35 60.3 33 56.9 
Race 
0.7637 Non White 12 20.7 9 15.5 
White 46 79.3 49 84.5 
Admitting Physician Facility 
0.9190 
ICU/Surgery <5 3.4 <5 3.4 
Medicine 18 31.0 16 27.6 
Other 38 65.5 40 69.0 
Diagnosis-related group (DRG) description 
0.8095 Non-Ventilation 47 81.0 48 82.8 
Ventilation 11 19.0 10 17.2 
Hospital admission year 
0.9494 
2010 10 15.5 9 15.5 
2011 18 37.6 21 36.2 
2012 30 51.7 28 48.3 
Comorbidities (during admission) 
0.8239 
Charlson score 
(during admission, 
median and IQR) 
4 2-6 4 2-7 
Elixhauser score 
(during admission, 
median and IQR) 
6 4-8 6 5-8 0.2870 
Comorbidities (6 months prior) 
0.4959 
Charlson score- 
History (6 months 
prior, median and 
IQR) 
4 2-8 4 1-7 
Elixhauser score- 
History (6 months 
prior, median and 
IQR) 
5 2-8 5 2-8 0.8413 
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Figure 2:  Case-control study design  
 
 
 
 
 
 
 
 
 
 
 
Adult (≥18 years) inpatients with 
primary diagnosis of bacteremia 
(n=2,986) 
Cases (n=58) 
Exclusions: 
 No antibiotic treatment 
within 2 days of hospital 
admission (n=291) 
 
Premier data (n=25,649) 
Excluded-  
1. Missing medical record or 
not eligible- 6 months before 
hospital admission (N=5,647) 
2. Non-adults and patients 
without primary bacteremic 
diagnosis (n=17,016) 
 
Patients receiving any antibiotic within 2 
days of hospital admission (n=2,695) 
Patients with no inpatient 
mortality (n=821) 
Controls (n=58) 
Patients meeting inclusion criteria  
(n=882) 
Exclusions- Non-
statin users and 
incident  statin 
users (patients 
without at least 90 
days of continuous 
outpatient statin 
use, one day gap 
allowed) (n=1,813) 
 
Patients with inpatient 
mortality (n=61) 
Matching on Disease Risk Scores 
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Figure 2:  Disease risk scores distribution among cases and controls 
 
 
 
Note: On the y-axis, 0 represent controls, while 1 represent cases. 
On the x-axis, estimated probability is the disease risk score. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 70 
 
 
Figure 3:  CART model predicting inpatient mortality risk based on continued 
during admission statin duration among patients with baseline pre-admission 
statin use of 90 days. 
  
 
Note: "in.days" represents "continued-during-admission statin therapy duration". 
The study included an equal number (n=58) of cases and controls, producing a 50% 
survival rate at the root node. The split at 1.5 days predicted patients with <2 days of 
continued-during-admission statin use (n=74, 64%) have 62.2% probability of 
inpatient mortality (n=46 of 74), while the patients with ≥2 days of continued-during-
admission statin use (n=42, 36%), have only 28.6% (n=12 of 42) chances of inpatient 
mortality. In other words, among bacteremic patients with existing statin use, inpatient 
survival was higher among those continuing statins for at least 2 days after the 
admission compared to those not continuing or with 1 day of use (71.4% vs. 37.8%) 
and. the odds of inpatient mortality was 76% lower (OR 0.24, 95% CI 0.11-0.55). 
 
The final DRS model equation for predicting inpatient mortality developed in patients 
not continuing statins during the admission. 
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Here y is the probability of inpatient mortality, α is the intercept, β’s are the 
coefficients on the independent variables and ε is standard error.   
 
Figure 4:  Cross-validated error rate vs. size of tree for analysis on statin users 
 
